BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company

Core Insights - BioLife Solutions, Inc. has acquired PanTHERA CryoSolutions, enhancing its biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology [1][3] - This acquisition marks the second from BioLife's Bioproduction Innovation Accelerator program, which aims to support early-stage disruptive technologies in bioproduction [3][4] Company Overview - BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy market, facilitating the commercialization of new therapies [7] - PanTHERA CryoSolutions specializes in cryopreservation solutions for cells, tissues, and organs, utilizing patented IRI technology to improve cell recovery and quality [5] Acquisition Details - BioLife is purchasing the remaining 90% of PanTHERA common shares for $9.3 million in cash and 241,355 shares of BioLife common stock, with potential additional stock worth up to $7.2 million based on achieving specific milestones [4] - The acquisition is expected to deepen BioLife's scientific capabilities and enhance its product offerings in the fast-growing CGT market [3][4] Technological Advancements - PanTHERA has launched its first-generation IRI technology and is developing next-generation formulations expected to launch within 18 months, which aim to improve cryopreservation outcomes and reduce reliance on liquid nitrogen [2][3] - The integration of PanTHERA's technology is anticipated to provide superior cryopreservation solutions, utilizing lower concentrations of DMSO while maintaining efficacy [2]